Fenretinide
- Generic Name
- Fenretinide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H33NO2
- CAS Number
- 65646-68-6
- Unique Ingredient Identifier
- 187EJ7QEXL
- Background
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
- Indication
Investigated for use/treatment in macular degeneration.
- Associated Conditions
- -
- Associated Therapies
- -
Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
- Conditions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2013-09-12
- Lead Sponsor
- California Cancer Consortium
- Target Recruit Count
- 21
- Registration Number
- NCT00387504
- Locations
- ๐บ๐ธ
City of Hope Medical Group, Pasadena, California, United States
๐บ๐ธCity of Hope Comprehensive Cancer Center, Duarte, California, United States
๐บ๐ธTexas Tech University Health Sciences Center, Lubbock, Texas, United States
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Stage I Adult Diffuse Large Cell LymphomaStage I Small Lymphocytic LymphomaStage II Adult Hodgkin LymphomaStage III Adult Diffuse Large Cell LymphomaStage III Mantle Cell LymphomaStage IV Adult Diffuse Large Cell LymphomaB-cell Chronic Lymphocytic LeukemiaContiguous Stage II Adult Burkitt LymphomaStage II Marginal Zone LymphomaNoncontiguous Stage II Adult Burkitt Lymphoma
- Interventions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00288067
- Locations
- ๐บ๐ธ
University of Washington Medical Center, Seattle, Washington, United States
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
- Conditions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- California Cancer Consortium
- Target Recruit Count
- 29
- Registration Number
- NCT00104923
- Locations
- ๐บ๐ธ
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
๐บ๐ธM. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
๐บ๐ธJoe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States
Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries
- Conditions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 40
- Registration Number
- NCT00098800
- Locations
- ๐บ๐ธ
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth
- First Posted Date
- 2004-09-10
- Last Posted Date
- 2012-07-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 5
- Registration Number
- NCT00003223
- Locations
- ๐บ๐ธ
Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States
๐บ๐ธUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
๐บ๐ธArizona Cancer Center, Tucson, Arizona, United States
Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome
- Conditions
- First Posted Date
- 2004-08-26
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 38
- Registration Number
- NCT00003601
- Locations
- ๐บ๐ธ
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT00003099
- Locations
- ๐บ๐ธ
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
- Conditions
- First Posted Date
- 2004-06-10
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 1500
- Registration Number
- NCT00002646
- Locations
- ๐บ๐ธ
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธBeckman Research Institute, City of Hope, Los Angeles, California, United States
๐บ๐ธCCOP - Atlanta Regional, Atlanta, Georgia, United States
Fenretinide in Treating Patients With Leukoplakia of the Mouth
- First Posted Date
- 2004-06-04
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 30
- Registration Number
- NCT00004161
- Locations
- ๐บ๐ธ
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
Fenretinide in Treating Patients With Cervical Neoplasia
- Conditions
- Interventions
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00003075
- Locations
- ๐บ๐ธ
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.